Skip to content

Risk factors for heart disease widespread among HIV patients

Skeletal muscle damage: emerging toxicity of HIV therapy?

Tenofovir/ddI interaction: pancreatitis death highlights risk

Ritonavir highest risk HIV protease inhibitor for lipid rises

Thymidine analogue mutations rare in first-line HAART failure

Once daily fos-amprenavir equal to nelfinavir

How common is lipodystrophy in people who have never taken HIV protease inhibitors?

Lipodystrophy has uneven impact on quality of life, says study

South African report says 9% of all deaths caused by HIV